Shares of The Chemours Company (NYSE:CC) recorded -0.99% loss during trading session on December 6th, 2018. The script traded as low as $25.22 and last traded at $26.88. 3.94 million shares changed exchanged hands during trading, a drop of -103.13% from the 30-day average session volume of 1.94M shares. The firm had previously closed at $27.15. The company has $171.20M outstanding shares, a price-to-earnings ratio of 4.51, price-to-earnings-growth ratio of 0.68 and a beta of 2.57. The company has a RSI of 26.41, ATR of 1.53 and a volatility of 4.97% this week. CC has a 52 week low price of $27.02 and a 52 week high price of $54.62.
Investors have identified the tech company The Chemours Company as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around 4.60B, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
The Chemours Company (CC) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For CC, the company has in raw cash 1.28 billion on their books with 0 currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 0 total, with 1.15 billion as their total liabilities. This figure have given the company a good sense of viability under numerous contexts.
CC were able to record 0 as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by 344 million. In cash movements, the company had a total of 0 as operating cash flow.
Potential earnings growth for The Chemours Company (CC)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, The Chemours Company recorded a total of 1.63 billion in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 0.03% coming in sequential stages and their sales for the third quarter reducing by -0.12%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 1.15 billion trying to sell their products during the last quarter, with the result yielding a gross income of 477 million. This allows shareholders to hold on to 171.20M with the revenue now reading 1560 cents per share.
Is the stock of CC attractive?
Having a look at the company’s valuation, the company is expected to record 5.57 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CC sounds very interesting.
In related news, Director BROWN RICHARD H bought 10,000 shares of the company’s stock in a transaction that recorded on December 3rd, 2018. The purchase was performed at an average price of 28.60, for a total value of 286,000. As the purchase deal closes, the President and CEO BROWN RICHARD H now sold 55,713 shares of the company’s stock, valued at 2,804,592. Also, SVP and CFO Newman Mark sold 43,675 shares of the company’s stock in a deal that was recorded on May 8th, 2018. The shares were sold at an average cost of 50.04 per share, with a total market value of 81,724. Following this completion of disposal, the President and CEO now holds 144,438 shares of the company’s stock, valued at 7,297,008. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.30%.
2 out of 13 analysts covering the stock have rated it a Buy, while 5 have maintained a Hold recommendation on The Chemours Company stock. 0 analysts has assigned a Sell rating on the CC stock. The 12-month mean consensus price target for the company’s shares has been set at $45.67.